A PYMNTS Company

US: FTC to study the impact of COPAs

By  |  October 21, 2019

The Federal Trade Commission issued orders to five health insurance companies and two health systems to provide information that will allow the agency to study the effects of certificates of public advantage (COPAs) on prices, quality, access, and innovation of healthcare services. The FTC also intends to study the impact of hospital consolidation on employee wages.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    COPAs are regulatory regimes, adopted by state governments that are intended to displace competition among healthcare providers. COPAs purport to immunize mergers and collaborations from antitrust scrutiny under the state action doctrine. FTC staff are engaged in an ongoing policy project to assess the effects of COPAs, which includes the study of COPAs recently approved for Ballad Health in Tennessee and Virginia, and Cabell Huntington Hospital in West Virginia.

    The five health insurance companies receiving orders from the FTC are: 1) Aetna, Inc., 2) Anthem, Inc., 3) BlueCross BlueShield of Tennessee, 4) Cigna Corporation, and 5) United Healthcare. These orders seek patient-level commercial claims data. The two health systems receiving orders from the FTC are: 1) Ballad Health and 2) Cabell Huntington Hospital, Inc. These orders seek aggregated patient billing and discharge data; health system employee wage data; and other information relevant for analyzing the health systems’ prices, quality, access, and innovation.

    Full Content: FTC

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.